Travere Therapeutics: Buy Rating On Back Of Filspari Expansion Towards FSGS

Core Viewpoint - The article initiates coverage on Travere Therapeutics, Inc. (NASDAQ: TVTX) with a Buy Rating, highlighting the significant potential of its drug sparsentan [2]. Company Overview - Travere Therapeutics is positioned in the pharmaceutical sector, focusing on innovative treatments, particularly with its lead drug sparsentan [2]. Investment Potential - The analysis emphasizes the massive potential of sparsentan, suggesting that it could be a key driver for the company's growth and stock performance [2].